Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more ...

Shares in Novo Nordisk fell as much as 3% on Friday after the Danish drugmaker and U.S. rival Eli Lilly agreed with the U.S.

Novo Nordisk said it currently expects an estimated negative low single-digit impact to global sales growth in 2026 after the ...

U.S. President Donald Trump, Eli Lilly and Novo Nordisk unveiled a deal on Thursday to slash the prices of popular GLP-1 ...

Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

Danish company vies with US drugmaker for control of Metsera as they seek edge in growing market for weight-loss drugs ...